ladiratuzumab vedotin

Drug Overview

Ladiratuzumab vedotin (also known as SGN-LIV1A) is an advanced, experimental cancer medication designed to treat solid tumors with high precision. It is widely considered a “Smart Drug” because it belongs to a modern class of treatments called Antibody-Drug Conjugates (ADCs).

Unlike traditional chemotherapy that travels through the whole body and affects both healthy and sick cells, this targeted therapy acts like a “guided missile.” It combines a specific immune system protein (the antibody) with a powerful cancer-killing medicine (the drug). This allows the treatment to find cancer cells specifically, attach to them, and deliver the medicine directly inside, sparing more of the surrounding healthy tissue.

• Generic Name: Ladiratuzumab vedotin
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Antibody-Drug Conjugate (ADC); Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Phase I/II Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how ladiratuzumab vedotin works, imagine the medication as a two-part system: a “seeker” and a “payload.”

At the molecular level, the process occurs in four specific steps:

1. Targeting the Receptor: The antibody portion of the drug is programmed to find a protein called LIV-1 (also known as SLC39B). LIV-1 is found in very high amounts on the surface of many breast and prostate cancer cells but is rarely found on healthy cells.
2. Binding and Entry: The drug travels through the blood until it “locks” onto the LIV-1 receptor on a cancer cell. Once attached, the cancer cell pulls the drug inside itself.
3. Releasing the Payload: Inside the cell, the “linker” that holds the two parts together is broken down by the cell’s own enzymes. This releases the active drug, called Monomethyl Auristatin E (MMAE).
4. Stopping Cell Division: MMAE is a potent microtubule inhibitor. Microtubules are like the “bones” of a cell that are needed for it to divide. By destroying these structures, the drug prevents the cancer cell from multiplying, eventually leading to the cell’s death (apoptosis).

FDA-Approved Clinical Indications

As an investigational drug, ladiratuzumab vedotin is not yet approved for general use. It is currently available to patients participating in strictly controlled clinical trials.

Oncological Uses (Investigational)

• Triple-Negative Breast Cancer (TNBC): For patients whose cancer has returned or spread (metastatic) after other treatments.
• Hormone Receptor-Positive Breast Cancer: For advanced cases that are LIV-1 positive.
• Advanced Solid Tumors: Including prostate, melanoma, and certain lung cancers that express the LIV-1 protein.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Ladiratuzumab vedotin is given by a medical professional in an infusion center or hospital.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Because the liver processes the MMAE payload, patients with liver issues are monitored very closely. Doses may be reduced or delayed if liver enzymes or bilirubin levels increase.
• Weight Changes: The dose is recalculated if a patient gains or loses a significant amount of weight.

Clinical Efficacy and Research Results

Clinical research from 2020 to 2025 has focused on how well this drug works for patients who have already tried several other therapies.

• Triple-Negative Breast Cancer (TNBC): Early clinical data indicates an Objective Response Rate (ORR) of approximately 25% to 35% when used as a single agent.
• Combination Therapy: Studies are currently testing ladiratuzumab vedotin alongside immunotherapies (like Pembrolizumab). Numerical data from early reports show that the combination may help more than 50% of patients achieve tumor shrinkage or stable disease.
• LIV-1 Expression: Research confirms that patients with higher levels of the LIV-1 protein on their tumors generally have better results from the treatment.

Safety Profile and Side Effects

Because ladiratuzumab vedotin delivers a powerful medicine, it can still affect some healthy parts of the body, particularly the nerves and blood cells.

Black Box Warning:

None. (Investigational drugs do not yet have formal Black Box Warnings, though other drugs in this class often carry warnings for lung inflammation or nerve damage).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Nausea: Mild stomach upset (usually manageable with medication).
• Alopecia: Thinning or loss of hair.
• Peripheral Neuropathy: Numbness, tingling, or “pins and needles” in the hands and feet.

Serious Adverse Events

• Neutropenia: A dangerous drop in white blood cells that increases the risk of infection.
• Hyperglycemia: Unusually high blood sugar levels.
• Infusion Reactions: Fever, chills, or dizziness during the IV drip.

Management Strategies

• Nerve Checks: Doctors perform regular “touch tests” to check for worsening neuropathy. If it becomes severe, the dose is lowered.
• Blood Monitoring: Regular blood tests are required to ensure white blood cell levels remain safe.

Research Areas

Ladiratuzumab vedotin is a major focus in Combination Immunotherapy research. Scientists are exploring if the way this drug kills cancer cells helps “prime” the immune system. When the cancer cell dies, it releases signals that act like a flare, helping T-cells find and attack other tumor cells. There is also early research into using the LIV-1 targeting technology to deliver Regenerative Medicine signals to specific tissues, though this is currently in the very early discovery phase.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• LIV-1 Expression Test: A biopsy sample is checked to see if the tumor has enough of the LIV-1 protein.
• Complete Blood Count (CBC): To check white and red blood cell levels.
• Liver Function Test (LFT): To ensure the liver can safely process the drug.

Precautions During Treatment

• Monitor Neuropathy: Tell your doctor immediately if you have trouble buttoning a shirt or picking up small objects.
• Infection Prevention: Avoid people who are sick, as your white blood cell count may drop.

“Do’s and Don’ts” List

• Do keep a daily log of any tingling in your fingers or toes.
• Do stay hydrated before and after your infusion.
• Don’t take new herbal supplements without asking your oncology team, as some can interfere with liver enzymes.
• Don’t ignore a fever over 100.4°F (38°C), as this could be a sign of a serious infection.

Legal Disclaimer

Standard Medical Information Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Ladiratuzumab vedotin is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects data available as of early 2026.